U.S. Patent and Trademark Office, U.S. DEPA Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10561628
iling Date		2005-12-20
First Named Inventor Charl		i KRUSE
Art Unit		
Examiner Name		
Attorney Docket Number		R1180/20049

					U.S.I	PATENTS			Remove	
Examiner Cite Initial* No Patent Number		Kind Code ¹			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pat of cited Docu	Releva		Columns,Lines wher nt Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publ		,				d button	Add	
				FOREIG	SN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patentee Applicant of cited Document	e or v	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	74
	1	10290025	DE		Τ1	2003-10-09	ST-ONGE et al.			
	2	02086107	wo		A2	2002-10-31	WOBUS et al.			
	3	02059278	wo		A2	2002-08-01	LUMELSKY et al.			E

2000-12-28 BONNER-WEIR et al.

A1

If you wis	h to a	dd additional Foreign Patent Document citation information please click the Add button Add				
		NON-PATENT LITERATURE DOCUMENTS Remove				
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (took, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					
	1 BONNER-WEIR et al., "In vitro cultivation of human silets from expanded ductal fascue", PNAS, vol. 97, (2000), pp.7999-9004					
	2 RAMIYA et al., "Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells", Nature Medicine, vol. 6, (2000), pp. 276-282					
	3	SORIA, "In-vitro differentiation of panoreatic B-cells", Differentiation (2001) 68: 205-219				

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

If you wish to add additional non-patent literature document citation information please click the Add button Add

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Not Code of USPD Potent Documents at even USPTO_COLV or MEPC 90.04. Tester does that issued the document, by the toe-lefter code (WPD)
Standard 87.3. "The dupresses parted countents the indication of the year of the right of the Emperor seep process the second random of the parted document."
*Indicat of countert by the appropriate symbols as indicated on the document under WPD Standard 87.16 if possible. "Application is to place a close must here if
English imaging serve resistance is all studies."

0078929

wo

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10561628
Filing Date		2005-12-20
First Named Inventor Charl		KRUSE
Art Unit		
Examiner Name		
Attorney Docket Number		B1180/20049

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.9	8 to make	the appro	priate selection(s):
---------------	----------	---------	-----------	-----------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/david m. tener/	Date (YYYY-MM-DD)	2006-05-25
Name/Print	David M. Tener	Registration Number	37054

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.